Clinical trial · Interventional
Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer
A Pilot Study Of Pirfenidone For The Treatment Of Radiation-Induced Fibrosis
NCT00020631CI-TRIAL-00010773completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Pirfenidone may prevent or lessen fibrosis caused by radiation therapy. PURPOSE: Pilot trial to study the effectiveness of pirfenidone in preventing or lessening fibrosis in patients who have undergone radiation therapy for cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Radiation Fibrosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| pirfenidone | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Regional post-radiation fibrosis of a specific body area (e.g., neck, back, or extremities)
* At least moderate impairment in at least 1 of the following principal functional abilities:
* Range of motion
* Strength
* Edema
* Swallowing
* Prior radiation for cancer received more than 6 months ago
* No evidence of recurrent or metastatic cancer
* No history of collagen vascular disease
* No positive antinuclear antibody
PATIENT CHARACTERISTICS:
Age:
* 18 and over
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Hepatitis B and C negative
Renal:
* Not specified
Other:
* HIV negative
* No evidence of second primary cancer
* No life-threatening situation requiring rehabilitation intervention
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* No concurrent anticancer immunotherapy
Chemotherapy:
* No concurrent anticancer chemotherapy
Endocrine therapy:
* No concurrent anticancer hormonal therapy
Radiotherapy:
* See Disease Characteristics
* No concurrent anticancer radiotherapy
Surgery:
* Not specified
Other:
* No other concurrent anticancer investigational agents
* Stable doses of medicine (e.g., non-steroidal anti-inflammatory drugs) currently being taken are allowedReferences
Publications (0)
Data not yet available
No reference posted for this study.